TCOV
BEAM icon

Trust Company of Vermont’s Beam Therapeutics BEAM Stock Holding History

Trust Company of Vermont’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200
Closed -$6.61K – 906
2024
Q1 		$6.61K Buy
+200
New +$6.23K ﹤0.01% 719

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Trust Company of Vermont's BEAM Position: Q2 2024 in Review

Trust Company of Vermont sold out of Beam Therapeutics (BEAM) in Q2 2024, closing a stake of 200 shares — an estimated $6.61K sold.

Trust Company of Vermont first reported a position in BEAM in Q1 2024 and held it in 1 quarter. The position peaked at $6.61K in Q1 2024. 214 funds tracked by Wall St. Rank hold BEAM as of Q2 2024.

  • Trust Company of Vermont reported no remaining Beam Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Trust Company of Vermont sold 200 Beam Therapeutics shares in Q2 2024, an estimated $6.61K.
  • Trust Company of Vermont first reported a position in Beam Therapeutics in Q1 2024 and held it in 1 quarter.
  • Trust Company of Vermont's Beam Therapeutics position peaked at $6.61K in Q1 2024.
  • 214 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2024.

Based on Trust Company of Vermont's 13F filing for Q2 2024, filed 9 Jul 2024.